[
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results",
    "summary": "-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in to",
    "url": "https://finnhub.io/api/news?id=0f842c93efbd64d8228f4c07305a09a11b8281ff562bc42ab663165e101a54fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762779600,
      "headline": "CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results",
      "id": 137395071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in to",
      "url": "https://finnhub.io/api/news?id=0f842c93efbd64d8228f4c07305a09a11b8281ff562bc42ab663165e101a54fb"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call",
    "summary": "Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w",
    "url": "https://finnhub.io/api/news?id=9c146eef541f6e41232681ef1fa93e47f59de0b77c570e6cdbcc869d53f80d10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762752711,
      "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call",
      "id": 137395072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w",
      "url": "https://finnhub.io/api/news?id=9c146eef541f6e41232681ef1fa93e47f59de0b77c570e6cdbcc869d53f80d10"
    }
  }
]